RCEL Stock Forecast & Price Target

AVITA Medical is viewed positively because its RECELL platform addresses a clear clinical need by enabling Spray-on Skin from a small sample within 30 minutes, reducing donor-site burden versus standard grafting and supporting adoption in most of the 140 US burn centers. The company’s fundamentals are improving as reimbursement has stabilized across all seven MACs, US RECELL volume rose ~11% sequentially to over 2,600 units in 2Q26, and record revenue of ~$21.7M grew 18% year over year while guidance was raised to $86M-$89M for FY26. Additional upside comes from a diversified and de-risked growth story: PermeaDerm and Cohealyx are broadening the revenue base, with PermeaDerm-I showing a 70% economic advantage, 96% lower preparation time, and comparable outcomes, yet the stock still trades at ~2.8x NTM EV/Sales versus peers at ~6.3x despite a modeled 22% CAGR.

AVITA Medical is viewed negatively because it remains heavily dependent on the RECELL system, making the business vulnerable if adoption in burn and full-thickness skin defect procedures proves uneven. Its growth case is still constrained by clinical and regulatory timing, limited capital, and persistent reimbursement friction from third-party payers, all of which can slow commercialization even where approvals already exist. Although the stock is framed against 12-24 month sales estimates at a discount to peers, the company’s narrow product focus and reliance on the US market outweigh the improving top-line narrative, despite growing Japan sales.